Literature DB >> 20309685

Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?

Massimo Salvatori, Germano Perotti, Luca Giovanella, Massimo Eugenio Dottorini.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20309685     DOI： 10.1007/s00259-010-1414-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake.

Authors:  S Chopra; M L Wastie; S Chan; R M Vincent; A Przeslak; A C Perkins; C S Ubhi
Journal:  Nucl Med Commun       Date:  1996-08       Impact factor: 1.690

2.  The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.

Authors:  Robbert B T Verkooijen; Frederik A Verburg; Johannes W van Isselt; Cornelis J M Lips; Jan W Smit; Marcel P M Stokkel
Journal:  Eur J Endocrinol       Date:  2008-06-20       Impact factor: 6.664

3.  The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.

Authors:  Ha T T Phan; Pieter L Jager; Jacqueline E van der Wal; Wim J Sluiter; John T M Plukker; Rudi A J O Dierckx; Bruce H R Wolffenbuttel; Thera P Links
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

4.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

Authors:  Glenn D Flux; Masud Haq; Sarah J Chittenden; Susan Buckley; Cecilia Hindorf; Kate Newbold; Clive L Harmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

5.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.

Authors:  H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

6.  Diagnostic performance of a new highly sensitive thyroglobulin immunoassay.

Authors:  A Iervasi; G Iervasi; A Bottoni; G Boni; C Annicchiarico; P Di Cecco; G C Zucchelli
Journal:  J Endocrinol       Date:  2004-08       Impact factor: 4.286

7.  Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.

Authors:  Luca Giovanella; Luca Ceriani; Antonella Ghelfo; Marco Maffioli; Franco Keller
Journal:  Clin Endocrinol (Oxf)       Date:  2007-06-11       Impact factor: 3.478

Review 8.  Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management.

Authors:  Luca Giovanella
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

9.  Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma.

Authors:  Luca Giovanella; Franco Keller; Luca Ceriani; Renato Tozzoli
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

Review 10.  Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

Authors:  B Brans; L Bodei; F Giammarile; O Linden; M Luster; W J G Oyen; J Tennvall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05       Impact factor: 9.236
View more
  1 in total

1.  A "new/old method" for TSH stimulation: could a third way to prepare DTC patients for (131)I remnant ablation possibly exist?

Authors:  Luca Giovanella; Arnoldo Piccardo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-17       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.